AstraZeneca and Abbisko collaborate on NSCLC combination therapy trial

Summary

AstraZeneca and Abbisko Therapeutics announced a strategic collaboration to study the combined use of Tagrisso and lumipodlin in non-small cell lung cancer patients. The trial represents a partnership to evaluate potential synergies between the two therapies.